Zorvec™ active is the first member of a novel class of fungicides to control diseases caused by oomycete pathogens.
Zorvec™ affects a novel target site with a completely new biochemical mode of action and has no cross-resistance with existing fungicides. It produces multiple effects on the pathogen’s life cycle for better efficacy, efficiency and length of control.
New chemistry, multiple advantages
- Novel target site, completely new biochemical mode of action
- No cross resistance with existing fungicides
- Zorvec™ binds in the Oxysterol-binding protein (OSBP)
- FRAC Group 49
Improved effectiveness, favourable environmental profile
Zorvec™ features a favourable environmental profile, being effective on target organisms at very low use rates and having very low toxicity to non-target organisms. Mammalian oral, neurological, developmental and dermal toxicity is low, as is avian and bee toxicity. When assessed on these and other criteria, Zorvec™ represents a highly effective oomycete disease control technology.
Zorvec™ active fungicide (oxathiapiprolin) is not registered for sale or use in all countries. No offer for sale, sale, or use of this product is permitted prior to issuance of the required country level registrations.